1、 HUANG H, LIU Q, ZHANG T, et al. Farnesylthiosalicylic acid-loaded albumin nanoparticle alleviates renal fibrosis by inhibiting Ras/Raf1/p38 signaling pathway[J]. Int J Nanomed, 2021(16): 6441-6453. HUANG H, LIU Q, ZHANG T, et al. Farnesylthiosalicylic acid-loaded albumin nanoparticle alleviates renal fibrosis by inhibiting Ras/Raf1/p38 signaling pathway[J]. Int J Nanomed, 2021(16): 6441-6453.
2、 ELZOGHBY A O, SAMY W M, ELGINDY N A. Albumin-based nanoparticles as potential controlled release drug delivery systems[J]. J Control Release, 2012, 157(2): 168-182. ELZOGHBY A O, SAMY W M, ELGINDY N A. Albumin-based nanoparticles as potential controlled release drug delivery systems[J]. J Control Release, 2012, 157(2): 168-182.
3、 ZHANG X, CHEN Q, ZHANG L,et al. Tubule-specific protein nanocages potentiate targeted renal fibrosis therapy[J]. J Nanobiotechnol, 2021, 19(1): 1-17. ZHANG X, CHEN Q, ZHANG L,et al. Tubule-specific protein nanocages potentiate targeted renal fibrosis therapy[J]. J Nanobiotechnol, 2021, 19(1): 1-17.
4、 HILL B D, ZAK A, KHERA E, et al. Engineering virus-like particles for antigen and drug delivery[J]. Curr Protein Pept Sc, 2018, 19(1): 112-127. HILL B D, ZAK A, KHERA E, et al. Engineering virus-like particles for antigen and drug delivery[J]. Curr Protein Pept Sc, 2018, 19(1): 112-127.
5、 JI C, ZHANG J, ZHU Y, et al. Exosomes derived from hucMSC attenuate renal fibrosis through CK1 delta/beta-TRCP-mediated YAP degradation[J]. Cell Death Dis, 2020, 11(5): 1-10. JI C, ZHANG J, ZHU Y, et al. Exosomes derived from hucMSC attenuate renal fibrosis through CK1 delta/beta-TRCP-mediated YAP degradation[J]. Cell Death Dis, 2020, 11(5): 1-10.
6、 TANG T T, LV L L, WANG B,et al. Employing macrophage-derived microvesicle for kidney-targeted delivery of dexamethasone: an efficient therapeutic strategy against renal inflammation and fibrosis[J]. Theranostics, 2019, 9(16): 4740-4755. TANG T T, LV L L, WANG B,et al. Employing macrophage-derived microvesicle for kidney-targeted delivery of dexamethasone: an efficient therapeutic strategy against renal inflammation and fibrosis[J]. Theranostics, 2019, 9(16): 4740-4755.
7、 SHARMA S, MASUD M K, KANETI Y V, et al. Extracellular vesicle nanoarchitectonics for novel drug delivery applications[J]. Small, 2021, 17(42): 2102220. SHARMA S, MASUD M K, KANETI Y V, et al. Extracellular vesicle nanoarchitectonics for novel drug delivery applications[J]. Small, 2021, 17(42): 2102220.
8、 TAN L, LAI X, ZHANG M, et al. A stimuli-responsive drug release nanoplatform for kidney-specific anti-fibrosis treatment[J]. Biomater Sci, 2019, 7(4): 1554-1564. TAN L, LAI X, ZHANG M, et al. A stimuli-responsive drug release nanoplatform for kidney-specific anti-fibrosis treatment[J]. Biomater Sci, 2019, 7(4): 1554-1564.
9、 TANAKA T, KOJIMA I, OHSE T, et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model[J]. Lab Invest, 2005, 85(10): 1292-1307. TANAKA T, KOJIMA I, OHSE T, et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model[J]. Lab Invest, 2005, 85(10): 1292-1307.
10、 NORDQUIST L, FRIEDERICH-PERSSON M, FASCHING A, et al. Activation of hypoxia-inducible factors prevents diabetic nephropathy[J]. J Am Soc Nephrol, 2015, 26(2): 328-338. NORDQUIST L, FRIEDERICH-PERSSON M, FASCHING A, et al. Activation of hypoxia-inducible factors prevents diabetic nephropathy[J]. J Am Soc Nephrol, 2015, 26(2): 328-338.
11、 ZHENG Z, DENG G, QI C, et al. Porous Se@SiO2 nanospheres attenuate ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) and inflammation by antioxidative stress[J]. Int J Nanomed, 2019(14): 215-229. ZHENG Z, DENG G, QI C, et al. Porous Se@SiO2 nanospheres attenuate ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) and inflammation by antioxidative stress[J]. Int J Nanomed, 2019(14): 215-229.
12、 SAIFI M A, PEDDAKKULAPPAGARI C S, AHMAD A, et al. Leveraging the pathophysiological alterations of obstructive nephropathy to treat renal fibrosis by cerium oxide nanoparticles[J]. ACS Biomater Sci Eng, 2020, 6(6): 3563-3573. SAIFI M A, PEDDAKKULAPPAGARI C S, AHMAD A, et al. Leveraging the pathophysiological alterations of obstructive nephropathy to treat renal fibrosis by cerium oxide nanoparticles[J]. ACS Biomater Sci Eng, 2020, 6(6): 3563-3573.
13、 WANG M, ZENG F, NING F, et al. Ceria nanoparticles ameliorate renal fibrosis by modulating the balance between oxidative phosphorylation and aerobic glycolysis[J]. J Nanobiotechnol, 2022, 20(1): 1-18. WANG M, ZENG F, NING F, et al. Ceria nanoparticles ameliorate renal fibrosis by modulating the balance between oxidative phosphorylation and aerobic glycolysis[J]. J Nanobiotechnol, 2022, 20(1): 1-18.
14、 NELSON B C, JOHNSON M E, WALKER M L, et al. Antioxidant cerium oxide nanoparticles in biology and medicine[J]. Antioxid, 2016, 5(2): 15. NELSON B C, JOHNSON M E, WALKER M L, et al. Antioxidant cerium oxide nanoparticles in biology and medicine[J]. Antioxid, 2016, 5(2): 15.
15、 WANG P, MIN D, CHEN G, et al. Inorganic nanozymes: prospects for disease treatments and detection applications[J]. Front Chem, 2021(9):773285. WANG P, MIN D, CHEN G, et al. Inorganic nanozymes: prospects for disease treatments and detection applications[J]. Front Chem, 2021(9):773285.
16、 MIDGLEY A C, WEI Y, ZHU D,et al. Multifunctional natural polymer nanoparticles as antifibrotic gene carriers for CKD therapy[J]. J Am Soc Nephrol, 2020, 31(10): 2292-2311. MIDGLEY A C, WEI Y, ZHU D,et al. Multifunctional natural polymer nanoparticles as antifibrotic gene carriers for CKD therapy[J]. J Am Soc Nephrol, 2020, 31(10): 2292-2311.
17、 MUMPER R J, CUI Z R. Genetic immunization by jet injection of targeted pDNA-coated nanoparticles[J]. Methods, 2003, 31(3): 255-262. MUMPER R J, CUI Z R. Genetic immunization by jet injection of targeted pDNA-coated nanoparticles[J]. Methods, 2003, 31(3): 255-262.
18、 GENG X, ZHANG M, LAI X, et al. Small-sized cationic miRi-PCNPs selectively target the kidneys for high-efficiency antifibrosis treatment[J]. Adv Healthc Mater, 2018, 7(21): 1800558. GENG X, ZHANG M, LAI X, et al. Small-sized cationic miRi-PCNPs selectively target the kidneys for high-efficiency antifibrosis treatment[J]. Adv Healthc Mater, 2018, 7(21): 1800558.
19、 XU Y, NIU Y, WU B, et al. Extended-release of therapeutic microRNA via a host-guest supramolecular hydrogel to locally alleviate renal interstitial fibrosis[J]. Biomaterials, 2021(275): 120902. XU Y, NIU Y, WU B, et al. Extended-release of therapeutic microRNA via a host-guest supramolecular hydrogel to locally alleviate renal interstitial fibrosis[J]. Biomaterials, 2021(275): 120902.
20、 HE Y, HUANG C, LIN X, LI J. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases[J]. Biochimie, 2013, 95(7): 1355-1359. HE Y, HUANG C, LIN X, LI J. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases[J]. Biochimie, 2013, 95(7): 1355-1359.
21、 WANG B, KOMERS R, CAREW R, et al. Suppression of microRNA-29 expression by tgf-beta 1 promotes collagen expression and renal fibrosis[J]. J Am Soc Nephrol, 2012, 23(2): 252-265. WANG B, KOMERS R, CAREW R, et al. Suppression of microRNA-29 expression by tgf-beta 1 promotes collagen expression and renal fibrosis[J]. J Am Soc Nephrol, 2012, 23(2): 252-265.
22、 LI Y F, JING Y, HAO J, et al. MicroRNA-21 in the pathogenesis of acute kidney injury[J]. Protein Cell, 2013, 4(11): 813-819. LI Y F, JING Y, HAO J, et al. MicroRNA-21 in the pathogenesis of acute kidney injury[J]. Protein Cell, 2013, 4(11): 813-819.
23、 LI C, WANG N, RAO P, et al. Role of the microRNA-29 family in myocardial fibrosis[J]. J Physiol Biochem, 2021, 77(3): 365-376. LI C, WANG N, RAO P, et al. Role of the microRNA-29 family in myocardial fibrosis[J]. J Physiol Biochem, 2021, 77(3): 365-376.
24、 PENG B, CHEN Y, LEONG K W. MicroRNA delivery for regenerative medicine[J]. Adv Drug Delivery Rev, 2015(88): 108-122. PENG B, CHEN Y, LEONG K W. MicroRNA delivery for regenerative medicine[J]. Adv Drug Delivery Rev, 2015(88): 108-122.
25、 YANG C, NILSSON L, CHEEMA M U, et al. Chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 attenuate unilateral ureteral obstruction-induced kidney injury in mice[J]. Theranostics, 2015, 5(2): 110-123. YANG C, NILSSON L, CHEEMA M U, et al. Chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 attenuate unilateral ureteral obstruction-induced kidney injury in mice[J]. Theranostics, 2015, 5(2): 110-123.
26、 STOKMAN G, QIN Y, RACZ Z, et al. Application of siRNA in targeting protein expression in kidney disease[J]. Adv Drug Delivery Rev, 2010, 62(14): 1378-1389. STOKMAN G, QIN Y, RACZ Z, et al. Application of siRNA in targeting protein expression in kidney disease[J]. Adv Drug Delivery Rev, 2010, 62(14): 1378-1389.
27、 SUBHAN M A, TORCHILIN V P. siRNA based drug design, quality, delivery and clinical translation[J]. Nanomed-Nanotechnol, 2020(29): 102239. SUBHAN M A, TORCHILIN V P. siRNA based drug design, quality, delivery and clinical translation[J]. Nanomed-Nanotechnol, 2020(29): 102239.
28、 ZHAO Z, WANG J, MAO H Q,et al. Polyphosphoesters in drug and gene delivery[J]. Adv Drug Delivery Rev, 2003, 55(4): 483-499. ZHAO Z, WANG J, MAO H Q,et al. Polyphosphoesters in drug and gene delivery[J]. Adv Drug Delivery Rev, 2003, 55(4): 483-499.
29、 BRODY H. GENE THERAPY[J]. Nature, 2018, 564(7735): S5-S5. BRODY H. GENE THERAPY[J]. Nature, 2018, 564(7735): S5-S5.
30、 WEI S, XU C, ZHANG Y, et al. Ultrasound assisted a peroxisome proliferator-activated receptor (PPAR)gamma agonist-loaded nanoparticle-microbubble complex to attenuate renal interstitial fibrosis[J]. Int J Nanomed, 2020(15): 7315-7327. WEI S, XU C, ZHANG Y, et al. Ultrasound assisted a peroxisome proliferator-activated receptor (PPAR)gamma agonist-loaded nanoparticle-microbubble complex to attenuate renal interstitial fibrosis[J]. Int J Nanomed, 2020(15): 7315-7327.
31、 WANG Z, LIN Q, DAI W, et al. Pioglitazone downregulates Twist-1 expression in the kidney and protects renal function of Zucker diabetic fatty rats[J]. Biomed Pharmacother, 2019(118): 109346. WANG Z, LIN Q, DAI W, et al. Pioglitazone downregulates Twist-1 expression in the kidney and protects renal function of Zucker diabetic fatty rats[J]. Biomed Pharmacother, 2019(118): 109346.
32、 LIU B C, LAN H Y, LV L L. Renal Fibrosis: Mechanisms and Therapies[M]. Springer Singapore, 2019. LIU B C, LAN H Y, LV L L. Renal Fibrosis: Mechanisms and Therapies[M]. Springer Singapore, 2019.
33、 VITIELLO P P, CARDONE C, MARTINI G, et al. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines[J]. J Exp Clin Canc Res, 2019, 38(1): 1-12. VITIELLO P P, CARDONE C, MARTINI G, et al. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines[J]. J Exp Clin Canc Res, 2019, 38(1): 1-12.
34、 WANG X, DENG B, YU M, et al. Constructing a passive targeting and long retention therapeutic nanoplatform based on water-soluble, non-toxic and highly-stable core-shell poly(amino acid) nanocomplexes[J]. Biomater Sci, 2021, 9(21): 7065-7075. WANG X, DENG B, YU M, et al. Constructing a passive targeting and long retention therapeutic nanoplatform based on water-soluble, non-toxic and highly-stable core-shell poly(amino acid) nanocomplexes[J]. Biomater Sci, 2021, 9(21): 7065-7075.
35、 QIAO H, SUN M, SU Z, et al. Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan[J]. Biomaterials, 2014, 35(25): 7157-7171. QIAO H, SUN M, SU Z, et al. Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan[J]. Biomaterials, 2014, 35(25): 7157-7171.
36、 LI J, ZHANG C, HE W, et al. Coordination-driven assembly of catechol-modified chitosan for the kidney-specific delivery of salvianolic acid B to treat renal fibrosis[J]. Biomater Sci, 2017, 6(1): 179-188. LI J, ZHANG C, HE W, et al. Coordination-driven assembly of catechol-modified chitosan for the kidney-specific delivery of salvianolic acid B to treat renal fibrosis[J]. Biomater Sci, 2017, 6(1): 179-188.
37、 GUO P, WANG J, GAO W, et al. Salvianolic acid B reverses multidrug resistance in nude mice bearing human colon cancer stem cells[J]. Mol Med Rep, 2018, 18(2): 1323-1334. GUO P, WANG J, GAO W, et al. Salvianolic acid B reverses multidrug resistance in nude mice bearing human colon cancer stem cells[J]. Mol Med Rep, 2018, 18(2): 1323-1334.
38、 FAN J M, NG Y Y, HILL P A, et al. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro[J]. Kidney Int, 1999, 56(4): 1455-1467. FAN J M, NG Y Y, HILL P A, et al. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro[J]. Kidney Int, 1999, 56(4): 1455-1467.
39、 LI R, LI Y, ZHANG J, et al. Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity[J]. J Control Release, 2020(320): 32-44. LI R, LI Y, ZHANG J, et al. Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity[J]. J Control Release, 2020(320): 32-44.
40、 LIN L, SUN Y, WANG D, et al. Celastrol ameliorates ulcerative colitis-related colorectal cancer in mice via suppressing inflammatory responses and epithelial-mesenchymal transition[J]. Front Pharmacol, 2016(6): 320. LIN L, SUN Y, WANG D, et al. Celastrol ameliorates ulcerative colitis-related colorectal cancer in mice via suppressing inflammatory responses and epithelial-mesenchymal transition[J]. Front Pharmacol, 2016(6): 320.
41、 LI S, ZHANG H, CHEN K, et al. Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges[J]. Drug Deliv, 2022, 29(1): 1142-1149. LI S, ZHANG H, CHEN K, et al. Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges[J]. Drug Deliv, 2022, 29(1): 1142-1149.
42、 WILLIAMS R M, SHAH J, NG B D, et al. Mesoscale nanoparticles selectively target the renal proximal tubule epithelium[J]. Nano Lett, 2015, 15(4): 2358-2364. WILLIAMS R M, SHAH J, NG B D, et al. Mesoscale nanoparticles selectively target the renal proximal tubule epithelium[J]. Nano Lett, 2015, 15(4): 2358-2364.
43、 SANCEY L, KOTB S, TRULLLET C, et al. Long-term in vivo clearance of gadolinium-based aguix nanoparticles and their biocompatibility after systemic injection[J]. ACS Nano, 2015, 9(3): 2477-2488. SANCEY L, KOTB S, TRULLLET C, et al. Long-term in vivo clearance of gadolinium-based aguix nanoparticles and their biocompatibility after systemic injection[J]. ACS Nano, 2015, 9(3): 2477-2488.
44、 OGAWA S, OTA Z, SHIKATA K, et al. High-resolution ultrastructural comparison of renal glomerular and tubular basement membranes[J]. Am J Nephrol, 1999, 19(6): 686-693. OGAWA S, OTA Z, SHIKATA K, et al. High-resolution ultrastructural comparison of renal glomerular and tubular basement membranes[J]. Am J Nephrol, 1999, 19(6): 686-693.
45、 KANWAR Y S, FARQUHAR M G. Presence of heparan sulfate in the glomerular basement membrane[J]. P Natl Acad Sci USA, 1979, 76(3), 1303-1307. KANWAR Y S, FARQUHAR M G. Presence of heparan sulfate in the glomerular basement membrane[J]. P Natl Acad Sci USA, 1979, 76(3), 1303-1307.
46、 SUH J H, MINER J H. The glomerular basement membrane as a barrier to albumin[J]. Nat Rev Nephrol, 2013, 9(8): 470-477. SUH J H, MINER J H. The glomerular basement membrane as a barrier to albumin[J]. Nat Rev Nephrol, 2013, 9(8): 470-477.
47、 CURRY F E, ADAMSON R H. Endothelial glycocalyx: permeability barrier and mechanosensor[J]. Ann Biomed Eng, 2012, 40(4): 828-839. CURRY F E, ADAMSON R H. Endothelial glycocalyx: permeability barrier and mechanosensor[J]. Ann Biomed Eng, 2012, 40(4): 828-839.
48、 SATCHELL S C, BRAET F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier[J]. Am J Physiol Renal, 2009, 296(5): F947-F956. SATCHELL S C, BRAET F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier[J]. Am J Physiol Renal, 2009, 296(5): F947-F956.
49、 WIGHT T N, POTTER-PERIGO S. The extracellular matrix: an active or passive player in fibrosis?[J] Am J Physiol Gastr L, 2011, 301(6): G950-955. WIGHT T N, POTTER-PERIGO S. The extracellular matrix: an active or passive player in fibrosis?[J] Am J Physiol Gastr L, 2011, 301(6): G950-955.
50、 BOOR P, OSTENDORF T, FLOEGE J. Renal fibrosis: novel insights into mechanisms and therapeutic targets[J]. Nat Rev Nephrol, 2010, 6(11): 643-656. BOOR P, OSTENDORF T, FLOEGE J. Renal fibrosis: novel insights into mechanisms and therapeutic targets[J]. Nat Rev Nephrol, 2010, 6(11): 643-656.
51、 WOO K-T, CHOONG H L, WONG K-S, et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases[J]. Kidney Int, 2012, 81(10): 1044-1045. WOO K-T, CHOONG H L, WONG K-S, et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases[J]. Kidney Int, 2012, 81(10): 1044-1045.
52、 FALKE L L, GHOLIZADEH S, GOLDSCHMEDING R, et al. Diverse origins of the myofibroblast-implications for kidney fibrosis[J]. Nat Rev Nephrol, 2015, 11(4): 233-244. FALKE L L, GHOLIZADEH S, GOLDSCHMEDING R, et al. Diverse origins of the myofibroblast-implications for kidney fibrosis[J]. Nat Rev Nephrol, 2015, 11(4): 233-244.
53、 STATER E P, SONAY A Y, HART C, et al. The ancillary effects of nanoparticles and their implications for nanomedicine[J]. Nat Nanotechnol, 2021, 16(11): 1180-1194. STATER E P, SONAY A Y, HART C, et al. The ancillary effects of nanoparticles and their implications for nanomedicine[J]. Nat Nanotechnol, 2021, 16(11): 1180-1194.
54、 KAMALY N, HE J C, AUSIELLO D A, et al. Nanomedicines for renal disease: current status and future applications[J]. Nat Rev Nephrol, 2016, 12(12): 738-753. KAMALY N, HE J C, AUSIELLO D A, et al. Nanomedicines for renal disease: current status and future applications[J]. Nat Rev Nephrol, 2016, 12(12): 738-753.
55、 HUANG L, YANG J, WANG T, GAO J, et al. Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery[J]. J Nanobiotechnol, 2022, 20(1): 49. HUANG L, YANG J, WANG T, GAO J, et al. Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery[J]. J Nanobiotechnol, 2022, 20(1): 49.
56、 ROBERTS T C, LANGER R, WOOD M J A. Advances in oligonucleotide drug delivery[J]. Nat Rev Drug Discov, 2020, 19(10): 673-694. ROBERTS T C, LANGER R, WOOD M J A. Advances in oligonucleotide drug delivery[J]. Nat Rev Drug Discov, 2020, 19(10): 673-694.
57、 CHEN T K, KNICELY D H, GRAMS M E. Chronic kidney disease diagnosis and management: a review[J]. J Am Med Assoc, 2019, 322(13): 1294-1304. CHEN T K, KNICELY D H, GRAMS M E. Chronic kidney disease diagnosis and management: a review[J]. J Am Med Assoc, 2019, 322(13): 1294-1304.
58、 UMPHREYS B D. Mechanisms of renal fibrosis[J]. Annu Rev Physiol, 2018(80): 309-326. UMPHREYS B D. Mechanisms of renal fibrosis[J]. Annu Rev Physiol, 2018(80): 309-326.
59、 FOREMAN K J, MARQUEZ N, DOLGERT A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories[J]. Lancet, 2018, 392(10159): 2052-2090. FOREMAN K J, MARQUEZ N, DOLGERT A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories[J]. Lancet, 2018, 392(10159): 2052-2090.
60、 DENG Y, LI N, WU Y, et al. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019[J]. Front endocrinol, 2021(12): 672350. DENG Y, LI N, WU Y, et al. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019[J]. Front endocrinol, 2021(12): 672350.
61、 RUIZ-ORTEGA M, RAYEGO-MATEOS S, LAMAS S, et al. Targeting the progression of chronic kidney disease[J]. Nat Rev Nephrol, 2020, 16(5): 269-288. RUIZ-ORTEGA M, RAYEGO-MATEOS S, LAMAS S, et al. Targeting the progression of chronic kidney disease[J]. Nat Rev Nephrol, 2020, 16(5): 269-288.
